Financial Performance - For the nine months ended September 30, 2022, the company's revenue was RMB 593,415,000, representing a 25.3% increase from RMB 473,661,000 in the same period of 2021[4] - Gross profit for the nine months ended September 30, 2022, was RMB 469,804,000, up 23.7% from RMB 379,611,000 year-on-year[4] - Operating profit for the nine months ended September 30, 2022, was RMB 123,929,000, compared to RMB 118,720,000 in the same period of 2021, reflecting a growth of 4.0%[4] - Profit attributable to equity holders for the nine months ended September 30, 2022, was RMB 104,658,000, an increase of 7.4% from RMB 96,969,000 in the previous year[4] - Basic earnings per share for the nine months ended September 30, 2022, was 18.68 cents, compared to 17.3 cents for the same period in 2021, marking an increase of 8.0%[4] - The company reported a total sales cost of RMB 123,611,000 for the nine months ended September 30, 2022, which is an increase from RMB 94,050,000 in the same period of 2021[4] - The company’s other income for the nine months ended September 30, 2022, was RMB 18,804,000, compared to RMB 13,990,000 in the same period of 2021, indicating a growth of 34.0%[4] - The company incurred tax expenses of RMB 18,577,000 for the nine months ended September 30, 2022, down from RMB 21,544,000 in the same period of 2021[8] - The company’s administrative expenses increased to RMB 90,494,000 for the nine months ended September 30, 2022, compared to RMB 60,497,000 in the same period of 2021, reflecting a rise of 49.5%[4] - The gross margin for the nine months ended September 30, 2022, was approximately 79.17%, a decrease of 0.97% from 80.14% in the previous year[13] - Selling expenses as a percentage of revenue increased to 46.2% from 45.3% in the previous year, attributed to higher advertising and promotional costs[13] Financial Position - As of September 30, 2022, the group maintained a strong financial position with cash and bank balances of approximately RMB 852,968,000 and a net asset value of approximately RMB 1,558,407,000[15] - The group had zero short-term bank borrowings as of September 30, 2022, resulting in a capital-to-debt ratio of 0%[16] Corporate Governance - The company adopted a code of conduct for securities trading by directors, ensuring compliance with GEM Listing Rules, with no known violations reported[29] - The company did not fully comply with GEM Listing Rules regarding corporate governance practices, specifically the separation of roles between the chairman and CEO, which are held by the same individual[30] - The audit committee, established in May 2001, is responsible for overseeing the financial reporting process and internal control systems, having reviewed the unaudited results for the period ending September 30, 2022[33] - No repurchase, sale, or redemption of the company's listed shares occurred during the nine-month period ending September 30, 2022[34] - The board consists of 6 executive directors and 3 independent non-executive directors as of the report date[35] Business Development - The company has completed the renovation of its biochemical extraction workshop, expected to commence production in 2022[14] - A new R&D inspection center has been established and was officially put into use in September 2021 for new product development and quality control[14] - Management believes that the Haikun Shenxi capsule has matured in the market and has replaced the compound Huonaoshush capsule as the group's best-selling product[17] - The group is committed to identifying potential business opportunities to create substantial results in the coming years[17]
吉林长龙药业(08049) - 2022 Q3 - 季度财报